Reneo Pharmaceuticals Inc (RPHM)

18.20 +0.90 (+5.20%) USD  |  NASDAQ  |  Oct 04, 16:00
1.88 -16.32 (-89.67%) Pre-Market: 20:00
More

Price Chart

Key Stats

View All Stats
Price and Performance
Market Cap --
52 Week High (Daily) Upgrade
52 Week Low (Daily) Upgrade
All-Time High (Daily) Upgrade
Year to Date Total Returns (Daily) Upgrade
1 Month Total Returns (Daily) Upgrade
1 Year Total Returns (Daily) --
Valuation
PE Ratio --
PE Ratio (Forward) Upgrade
PS Ratio --
Price to Book Value --
EV to EBITDA Upgrade
Dividend
Dividend --
Dividend Yield (Forward) Upgrade
Financials
Revenue (5 Year Growth) Upgrade
Revenue (Quarterly YoY Growth) Upgrade
EPS Diluted (5 Year Growth) Upgrade
EPS Diluted (Quarterly YoY Growth) Upgrade
Debt to Equity Ratio --
Return on Equity Upgrade
Return on Assets Upgrade
Risk
Beta (5Y) Upgrade
Max Drawdown (5Y) --

Ratings

Y-Rating Upgrade
Value Score Upgrade
Fundamental Score Upgrade
Valuation (Hist. Mult.) Upgrade

Profile

Reneo Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
URL https://www.reneopharma.com
Investor Relations URL N/A
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Nov. 13, 2024 (est.)
Last Earnings Release Aug. 13, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ratings

Y-Rating Upgrade
Value Score Upgrade
Fundamental Score Upgrade
Valuation (Hist. Mult.) Upgrade

Profile

Reneo Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
URL https://www.reneopharma.com
Investor Relations URL N/A
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Nov. 13, 2024 (est.)
Last Earnings Release Aug. 13, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A